Arbutus Biopharma Corporation (ABUS) Social Stream
Arbutus Biopharma Corp (ABUS) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ABUS.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-08 | 5 | $9 | $4 | $6 | $2.98 | 101.34% |
| 2021-12-02 | 5 | $9 | $4 | $6.625 | $2.98 | 122.32% |
| 2021-12-29 | 5 | $9 | $4 | $6.1 | $2.98 | 104.7% |
| 2022-02-02 | 5 | $9 | $4 | $6.3 | $2.98 | 111.41% |
| 2022-03-03 | 4 | $9 | $5 | $6.875 | $2.98 | 130.7% |
| 2022-03-07 | 4 | $9 | $5 | $7 | $2.98 | 134.9% |
| 2022-03-14 | 4 | $9 | $5 | $7.125 | $2.98 | 139.09% |
The Trend in the Analyst Price Target
ABUS's average price target has moved up $1.05 over the prior 42 weeks.
ABUS reports an average of 94.42% for its upside potential over the past 49 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-05-22 | 3 | 10 | 3.5 | 6.07 | 2.74 | 121.53% |
| 2021-07-03 | 7 | 10 | 3.5 | 6.07 | 2.95 | 105.76% |
| 2021-08-07 | 7 | 10 | 3.5 | 5.92 | 3.01 | 96.68% |
| 2021-08-28 | 6 | 10 | 3.5 | 5.90 | 3.33 | 77.18% |
| 2021-09-11 | 6 | 10 | 3.5 | 5.90 | 4.38 | 34.7% |
ABUS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 4 | 0 | 0 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
ABUS's average broker recommendation rating improved by 1.14 over the prior 35 weeks.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ABUS as an investment opportunity.
- In the context of all US stocks, Arbutus Biopharma Corp's average analyst price target is greater than 32.8% of them.
- ABUS has a lower variance in analysts' estimates than -465.21% of all US stocks.
- To contextualize these metrics, consider that out of Healthcare stocks, Arbutus Biopharma Corp's number of analysts covering the stock is higher than 216.12% of them.
- Arbutus Biopharma Corp's upside potential (average analyst target price relative to current price) is higher than 266.44% of Pharmaceutical Products stocks.
Stocks similar to Arbutus Biopharma Corp in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ABEO, VIGL, and TCRX.
What is the outlook for ABUS? Use POWR Ratings for clearer insight into price direction.